The latest price target for Panbela Therapeutics (OTCQB:PBLA) was reported by HC Wainwright & Co. on August 15, 2024. The analyst firm set a price target for $0.00 expecting PBLA to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Panbela Therapeutics (OTCQB:PBLA) was provided by HC Wainwright & Co., and Panbela Therapeutics reiterated their neutral rating.

The last upgrade for Panbela Therapeutics Inc happened on March 20, 2023 when Maxim Group raised their price target to $1.5. Maxim Group previously had a hold for Panbela Therapeutics Inc.

The last downgrade for Panbela Therapeutics Inc happened on May 16, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for Panbela Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Panbela Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Panbela Therapeutics was filed on August 15, 2024 so you should expect the next rating to be made available sometime around August 15, 2025.

While ratings are subjective and will change, the latest Panbela Therapeutics (PBLA) rating was a reiterated with a price target of $0.00 to $0.00. The current price Panbela Therapeutics (PBLA) is trading at is $0.33, which is out of the analyst’s predicted range.